**Core Concept:** The 'ABVD' regimen is a combination chemotherapy regimen used in the treatment of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It stands for:

A. doxorubicin (Adriamycin) - an anthracycline antibiotic that interferes with DNA synthesis and causes cell death
B. bleomycin - a cytotoxic drug that works by inhibiting DNA and RNA synthesis, damaging cell membranes, and causing free radical formation
C. vincristine - a vinca alkaloid that inhibits microtubule assembly, disrupting cell division and causing cell death
D. prednisolone - a corticosteroid that suppresses the immune system and inhibits inflammation, also inducing apoptosis in tumor cells

**Why the Correct Answer is Right:** The ABVD regimen is an effective combination therapy for Hodgkin's lymphoma and non-Hodgkin's lymphoma due to the following reasons:

1. Doxorubicin interferes with DNA synthesis, causing cell death in rapidly dividing cells like tumor cells.
2. Bleomycin works through multiple mechanisms, including inhibiting DNA and RNA synthesis, damaging cell membranes, and causing free radical formation, leading to cell death.
3. Vincristine inhibits the assembly of microtubules, disrupting cell division and causing cell death.
4. Prednisolone suppresses the immune system, targets inflammatory pathways, and induces apoptosis in tumor cells.

**Why Each Wrong Option is Incorrect:**

A. Option A (etoposide) is a topoisomerase II inhibitor, targeting DNA replication, not cell division. It is not as effective as bleomycin in causing cell death.
B. Option B (cyclophosphamide) is an alkylating agent, alkylating nitrogenous bases in DNA and RNA, causing cross-linking and cell death. It is not as effective as doxorubicin in causing cell death.
C. Option C (methotrexate) is an antimetabolite, interfering with purine and pyrimidine synthesis, causing cell death. It is not as effective as prednisolone in suppressing the immune system and targeting inflammatory pathways.
D. Option D (cyclophosphamide) is an alkylating agent, alkylating nitrogenous bases in DNA and RNA, causing cross-linking and cell death. It is not as effective as bleomycin in causing cell death.

**Clinical Pearl:** The ABVD regimen is a widely recognized and successful treatment approach due to its synergistic effect on tumor cell death and immunosuppression. It targets both the cancer cells and the immune system, making it a robust treatment modality for lymphoma patients.